Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind (Within Dose Groups), Randomized, Placebo-controlled Single Increasing Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Subcutaneous Administration of BIBN 4096 (Dosage: 2.5 - 30 mg)

NCT02194348 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02194348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02194348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind (Within Dose Groups), Randomized, Placebo-controlled Single Increasing Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Subcutaneous Administration of BIBN 4096 (Dosage: 2.5 - 30 mg)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2000
Completion date
Not reported
Enrollment
12 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy